Ephraim J. Fuchs

Ephraim J. Fuchs

Oncology

401 North Broadway Street, Weinberg BLDG
Weinberg BLDG
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

TEMPORARY REMOVAL: Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

TEMPORARY REMOVAL: Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

Journal: Transplantation and cellular therapy

Published: August 24, 2025

Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

Journal: Transplantation and cellular therapy

Published: August 24, 2025

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Journal: Transplantation and cellular therapy

Published: July 25, 2025

Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.

Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.

Journal: Transplantation and cellular therapy

Published: February 15, 2025

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with highdose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapy.

Journal: Haematologica

Published: January 24, 2025

Meeting Report: The Sixth International Sam Strober Workshop on Clinical Immune Tolerance.

Meeting Report: The Sixth International Sam Strober Workshop on Clinical Immune Tolerance.

Journal: Transplantation

Published: January 13, 2025

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.

Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.

Journal: Blood advances

Published: October 11, 2024

Immune-related encephalitis after immune checkpoint inhibitor therapy.

Immune-related encephalitis after immune checkpoint inhibitor therapy.

Journal: The oncologist

Published: January 29, 2024

TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.

TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.

Journal: Nature

Published: April 19, 2023

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia.

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia.

Journal: Blood

Published: March 10, 2023

Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101.

Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101.

Journal: Transplantation and cellular therapy

Published: February 07, 2023

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.

Journal: Heliyon

Published: January 27, 2023

Showing 1-12 of 116

Last Updated: 09/26/2026